Skip to main content
. 2016 Jun 14;7(28):44266–44276. doi: 10.18632/oncotarget.10023

Figure 5. Silencing of CD276 compromises the tumor progression of CRC in vitro.

Figure 5

A. Efficacy of RNA interference in LOVO and HT29 cells was verified by Western blotting. B. Silencing of CD276 inhibited proliferation in LOVO and HT29 cells detected by CCK-8 assays (*P < 0.05, **P < 0.01). C. Silencing of CD276 increased the caspase-3/7 activity of LOVO and HT29 cells compared with siRNA control transfected cells (**P < 0.01). Inhibition of CD276 significantly decreased the migratory D. and invasion E. ability of LOVO and HT29 cells (*P < 0.05). Data represent means ± S.D. of at least three independent experiments.